Abstract and Introduction Abstract. Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially ...

Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

Introduction Previous studies have demonstrated that one anastomosis gastric bypass (OAGB) is not inferior to Roux-en-Y gastric bypass (RYGB) in treating obesity. However, high level evidence ...

Roux-en-Y gastric bypass: limb length and weight loss. Arq Bras Cir Dig. 2014;27 Suppl 1:56-8. 19 Van de Laar AW, Dollé MH, de Brauw LM, Bruin SC, Acherman YI. Which baseline weight should be ...

Pharmacokinetic Considerations in Roux-en-Y Gastric Bypass Patients. April Smith; Brian Henriksen; Andrew Cohen. Disclosures. Am J Health Syst Pharm. 2011;68(23):2241-2247. ...

Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study ...

Britain is in the grip of a gastric flu outbreak which has spread from hospitals in Scotland to the south coast, health chiefs said today. Levels of the virus, which has already affected 12 ...

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.

However, this has had relatively little impact on the workload associated with gastric cancer, which has remained fairly constant, reflecting the ageing population. 22 Data from the Office for ...